Biotech entity

Nuvation Bio

Company NUVB

clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Nuvation Bio, all published on September 7, 2026.

Last mentioned: 4d ago

Entity pulse

Recent coverage · Nuvation Bio

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Nuvation Bio

clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Nuvation Bio, all published on September 7, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Nuvation Bio. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Coverage Highlights Market Divergence

    Financial media report on the stock's surge and note some Wall Street price targets are more upbeat than Cramer's caution.

  2. Cramer Calls NUVB 'Pure Speculation'

    On CNBC's Mad Money, Jim Cramer warns Nuvation Bio trades on what pipeline drugs might do someday rather than steady revenue.

  3. FDA Grants Fast Track Designation to Safusidenib

    Nuvation Bio's experimental brain cancer drug safusidenib receives FDA Fast Track status for IDH1-mutant glioma.

Stories mentioning Nuvation Bio 1

Nuvation Bio is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.